NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

BS. We have been paying Advent for years! Not good utilization of funds as opposed to activating CRL. And that too for approximately 5% of the global oncology market vs 50%. And not to mention all the margin pressures that will typically come in the U.K. with the reimbursements unlike US.

DNDN had many other issues. The biggest being manual process for every dose unlike NWBO. Hence cost control was next to impossible and that’s what lead to their demise rather. NWBO production doesn’t have these issues. Plus DNDN went after prostate cancer which is not an unmet need. There are a bunch of approved treatments and the long term survival odds are very good. Over 90% 5-year survival rate, I think. So it was not going to fly anyway with the cost/benefit calculations. We don’t have any of these issues to deal with.